子宮頸部異形成の世界市場規模：診断別、エンドユーザー別、地域別、範囲および予測

子宮頸部異形成の市場規模と予測

子宮頸部異形成市場規模は2024年に5億2,268万米ドルと評価され、2026年から2032年にかけてCAGR 7%で成長し、2032年には8億5,506万米ドルに達すると予測される

子宮頸がんに対する消費者の意識の高まりが、子宮頸部異形成市場の成長につながりました。さらに、ワクチン接種、社会動員、検診、地域教育に関する政府の取り組み、HPV感染の増加も子宮頸部異形成の診断拡大につながりました。この調査レポートは、子宮頸部異形成市場の全体的な評価を提供しています。セグメント、市場関連動向、市場促進要因、抑制要因、機会、競合情勢などを詳細に分析しています。

世界の子宮頸部異形成市場定義

子宮頸部異形成は、子宮頸部の細胞の異常増殖によって特定される前がん状態です。子宮頸部異形成は、子宮頸部上皮内新形成としても認識されています。治療と定期的な診断により、がんになる前に改善することができます。子宮頸部異形成は年齢に関係なく発症しますが、25～35歳の女性に多くみられます。子宮頸部異形成は、ヒトパピローマウイルス（HPV）感染によって誘発される性感染症です。自覚症状はなく、無症状です。

子宮頸部異形成は、感染する細胞の種類によって、腺房細胞病変と上皮内病変の2つに分類されます。この疾患は、パップテスト、HPV検査、コルポスコピーによって診断することができます。子宮頸部異形成は、異常部位の破壊と除去によって治療できる疾患です。手術、放射線療法、化学療法、薬物療法、アブレーション療法、切除術（異常部位の摘出）の3つが標準的な治療法です。治療法にはさまざまな種類があり、がんの進行度や悪性度によって必要な手術法が異なります。

VMRの中身

業界レポートの中身は？

当社のレポートには、ピッチ作成、ビジネスプランの作成、プレゼンテーションの構築、提案書の作成に役立つ実用的なデータと将来を見据えた分析が含まれています。

世界の子宮頸部異形成市場概要

子宮頸部異形成は、がんの診断と治療の分野で最も急成長している市場セグメントの1つです。子宮頸がんは前がん段階で、早期発見により効果的に治癒することができます。この点に関する消費者の意識の高まりが、予測期間における子宮頸部スクリーニング検査の需要向上につながりました。さらに、様々な先進国の政府機関は、死亡率を低下させることで国民の生活の質を高めるために検診プログラムを実施しています。さらに、子宮頸部異形成を含む慢性疾患の早期発見のための政府協会からの勧告は、予測期間にわたって子宮頸部異形成市場全体を牽引している主な要因の1つです。

市場の成長を制限するような制約や障壁も存在します。承認待ち、時間のかかる規制遵守による治療薬の入手不能、子宮頸部異形成市場の研究開発に必要な高コストなどの要因が、世界の子宮頸部異形成市場全体の成長を妨げる潜在的な抑制要因となっています。とはいえ、技術の絶え間ない開発と新興国市場の未開発の可能性は、有利な成長機会を提供します。

目次

第1章 世界の子宮頸部異形成市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の子宮頸部異形成市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界の子宮頸部異形成市場、診断別

• 概要
• 診断検査
  • HPV検査
  • パップスメア検査
  • 生検検査
• 診断機器
  • コルポスコープ

第6章 世界の子宮頸部異形成市場：エンドユーザー別

• 概要
• 病院
• 診断センター
• 外来手術センター
• その他

第7章 世界の子宮頸部異形成市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東

第8章 世界の子宮頸部異形成市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第9章 企業プロファイル

• QIAGEN
• F. Hoffmann La-Roche Ltd.
• Quest Diagnostics
• Becton, Dickinson and company
• Abbott Healthcare Pvt. Ltd
• OncoHealth Corporation, Inc.
• Hologic, Inc.

第10章 付録

• 関連調査

Cervical Dysplasia Market Size And Forecast

Cervical Dysplasia Market size was valued at USD 522.68 Million in 2024 and is projected to reach USD 855.06 Million by 2032, growing at a CAGR of 7% from 2026 to 2032

Growing consumer awareness regarding cervical cancer has led to risen growth of the Cervical Dysplasia Market. Furthermore, the government initiatives on vaccination, social mobilization, screening, and community education, and the increasing occurrence of HPV infection have also led to an expansion in the diagnosis of Cervical Dysplasia. The Global Cervical Dysplasia Market report provides a holistic evaluation of the market. The report provides an indepth analysis on the segments, market related trends, market drivers, restraints, opportunities along with the competitive landscape.

Global Cervical Dysplasia Market Definition

Cervical Dysplasia is a precancerous condition identified by abnormal growth of cells on the cervix. Cervical Dysplasia is also recognized as cervical intraepithelial neoplasia. It can be rectified before it becomes cancerous, by treatment and regular diagnosis. It usually strikes women of any age but more frequently between 25 to 35 years of age in women. Cervical Dysplasia is a sexually communicated disease-induced due to Human papillomavirus (HPV) infection. It does not show any symptoms, they are asymptomatic.

Cervical Dysplasia is classified in two varieties based on the type of cells it affects, involves glandular cell lesions and intraepithelial lesions. This condition can be diagnosed by a Pap test, HPV test, and colposcopy. Cervical Dysplasia is a condition that can be treated by the destruction and removal of the abnormal area. TSurgery, radiation therapy, chemotherapy, or medication combinations, ablation therapy, and resection (expulsion of the aberrant region) are the three types of standard treatment. There are various sorts of treatment alternatives, and the kind of surgical technique required relies on the stage and grade of cancer growth.

What's inside a VMR

industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Cervical Dysplasia Market Overview

Cervical Dysplasia makes for one of the fastest-growing market segments in the area of cancer diagnosis and treatment. Cervical cancer is a precancerous stage and it can be effectively cured by early detection. Growing consumer awareness in this regard has headed to improved demand for cervical screenings in the forecast period. Moreover, government organizations in various developed countries administer screening programs in order to enhance the quality of life of the population by reducing the mortality rate. Furthermore, recommendations from government associations for early detection of chronic diseases including Cervical Dysplasia is one of the primary factors that is driving the overall Cervical Dysplasia Market over the forecast period.

There are certain constraints and barriers experienced that will limit the market growth. The factors such as pending approvals, unavailability of a therapeutic drug due to time-consuming regulatory compliance, and the high cost required for research and development in the market for Cervical Dysplasia are the potential restraints hampering the overall growth of the global Cervical Dysplasia Market. Nevertheless, the continuous developments in technologies, and untapped potential in emerging markets offer favorable growth opportunities.

Global Cervical Dysplasia Market: Segmentation Analysis

The Global Cervical Dysplasia Market is Segmented on the basis of Diagnostic, End-User, And Geography.

Cervical Dysplasia Market, By Diagnostic

• Diagnostic Tests
• Diagnostic Devices

Based on Diagnostic, the market is bifurcated into Diagnostic Tests, Diagnostic Devices. The diagnostic tests segment holds the largest market share during the forecast period. The factors that can be attributed to its efficacy, flexibility, reimbursement policies, and cost-effectiveness are accelerating the demand for this segment.

Cervical Dysplasia Market, By End-User

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers
• Others

Based on End-User, the market is bifurcated into Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, and Others. The hospital segment accounts for the largest market share through the forecast years. The factors that can be attributed to the availability of technologically advanced diagnostic devices and tests and the presence of various reimbursement policies enhance the demand for this segment.

Cervical Dysplasia Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of regional analysis, the global Cervical Dysplasia Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America holds the largest market share. The technological advancements, increase in prevalence of various associated diseases, rising awareness and screening programs, and ongoing projects will boost the market in the North American region.

Key Players

The "Global Cervical Dysplasia Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as QIAGEN, F. Hoffmann La-Roche Ltd., Quest Diagnostics, Becton, Dickinson and company, Abbott Healthcare Pvt. Ltd, OncoHealth Corporation, Inc., and Hologic, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. Key development strategies, market share analysis, and market positioning analysis of the aforementioned competitors internationally are also included in the competitive landscape section.

Key Developments

• Both ASKA Pharmaceutical and KinoPharma, both Japanese pharmaceutical giants, agreed to a partnership agreement in January 2020 for the development and commercialization of medication candidates for cervical dysplasia in the market, which is now in the preclinical phase at KinoPharma. As part of the arrangement, ASKA will acquire exclusive rights to distribute the drug in Japan and will assist in the co-development of prospective therapeutic candidates in the future, while KinoPharma will earn upfront payments for the exclusive licencing.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CERVICAL DYSPLASIA MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL CERVICAL DYSPLASIA MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL CERVICAL DYSPLASIA MARKET, BY DIAGNOSTIC

• 5.1 Overview
• 5.2 Diagnostic Tests
  • 5.2.1 HPV Test
  • 5.2.2 Pap Smear Test
  • 5.2.3 Biopsy Test
• 5.3 Diagnostic Devices
  • 5.3.1 Colposcope

6 GLOBAL CERVICAL DYSPLASIA MARKET, BY END-USER

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Diagnostic Centers
• 6.4 Ambulatory Surgical Centers
• 6.5 Others

7 GLOBAL CERVICAL DYSPLASIA MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East

8 GLOBAL CERVICAL DYSPLASIA MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 QIAGEN
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 F. Hoffmann La-Roche Ltd.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Quest Diagnostics
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Becton, Dickinson and company
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Abbott Healthcare Pvt. Ltd
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 OncoHealth Corporation, Inc.
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Hologic, Inc.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments

10 Appendix

• 10.1 Related Research